Paramita Therapeutics, Inc. (Paramita), founded by Drs. Sang Van and Jack Bui, began operations in 2018. Paramita is an early-stage biotech startup focused on the development of novel targeted immunotherapies using our proprietary water-soluble multivalent conjugation platform technologies. Our mission is to eradicate cancer. In late 2018, we secured pre-seed funding, developed our new water-soluble multivalent platform technologies, and generated proof-of-concept data in mice. In 2020, Covid-19 came, and we had to shut down our laboratory. In 2021, Paramita was seed-funded by National Science Foundation (NSF) through a Phase 1 small business innovation research (SBIR) award to develop multivalent peptide conjugates for a dual-function therapeutic and vaccine product for COVID-19. We completed the SBIR grant in 2022. Now, we are actively seeking additional funding to complete preclinical studies and toxicology studies of the dual-function targeted cancer drug conjugates and vaccine products for advanced prostate and ovarian cancer.